Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study of an Anti OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis

Next Previous
Trial Profile

A Phase 2a, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study of an Anti OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlitelimab (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Kymab

Most Recent Events

  • 25 Oct 2023 Results of safety and efficacy of amlitelimab for atopic dermatitis, published in the British Journal of Dermatology
  • 18 Jul 2023 Results reporting safety and efficacy data over 16 weeks published in the British Journal of Dermatology
  • 21 Mar 2023 Results assessing safety of Amlitelimab in a Phase 2a Clinical Trial of Patients With Moderate-to-Severe Atopic Dermatitis presented at the American Academy of Dermatology annual Meeting 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top